
BioNTech appoints chief financial officer
pharmafile | September 2, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | BioNTech, Sierk Pötting
German biopharma firm BioNTech has announced that Sierk Pötting will be joining its management team as its chief financial officer, succeeding Michael Kring.
Pötting began his career as a consultant with McKinsey before moving over to work with Novartis. For the past several years he has served as CFO and VP at Sandoz in the US.
Helmut Jeggle, chair of the supervisory board at BioNTech says: “We are very pleased to strengthen our management team with someone with his background and look forward to working with Mr Pötting. The timing of his joining BioNTech is perfect for the company’s development – Sierk will help us position the company strongly for the long term.”
Pötting adds: “In my view, BioNTech is one of today’s most exciting cancer research groups using integrated diagnostic and immunotherapeutic technologies. I am thrilled to have the opportunity to join this company on its journey to the future.”
Kring will remain with the company until the end of 2014 as a member of its board.
Related Content

BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours
BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise …

BioNTech and Autolus announce CAR T-cell therapy collaboration
BioNTech and Autolus Therapeutics have announced that they have entered a strategic collaboration intended to …

BioNTech achieves milestone at vaccine manufacturing site in Rwanda
BioNTech has announced that it has reached the next milestone in the establishment of its …






